FDA Accepts Supplemental Application for Biogen's SKYCLARYS
The FDA has accepted a supplemental application (NDA216718) for Biogen's SKYCLARYS, containing omaveloxolone.
Asset / Drug
Drug and asset intelligence for SKYCLARYS with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.